Upstream Bio (UPB) Interest Expenses (2023 - 2026)
Upstream Bio (UPB) posted quarterly Interest Expenses of $21.2 million for Q1 2026, up 179.53% year-over-year from $7.6 million in Q1 2025, and down 86.92% quarter-over-quarter from $162.3 million in Q4 2025.
Upstream Bio (UPB) Interest Expenses (2023 - 2026) Analysis & Trends
Upstream Bio's Interest Expenses history runs 4 years deep, the most recent figure standing at $21.2 million for Q1 2026.
- In Q1 2026, Interest Expenses rose 179.53% year-over-year to $21.2 million; the TTM figure through Mar 2026 stood at $21.2 million (up 179.53% YoY), while the FY2025 annual figure was $162.3 million, up 127.71% from the prior year.
- Interest Expenses for Q1 2026 stood at $21.2 million, down from $162.3 million in the prior quarter.
- The five-year high for Interest Expenses was $162.3 million in Q4 2025, with the low at $7.6 million in Q1 2025.
- The 4-year median for Interest Expenses is $39.7 million (2023), against an average of $59.5 million.
- The sharpest annual moves came in 2024 and 2025: Interest Expenses surged 79.53% in 2024, then jumped 183.66% in 2025.
- Upstream Bio's Interest Expenses stood at $39.7 million in 2023, then soared by 79.53% to $71.3 million in 2024, then surged by 127.71% to $162.3 million in 2025, then slumped by 86.92% to $21.2 million in 2026.
- Business Quant data shows UPB's Interest Expenses at $21.2 million in Q1 2026, $162.3 million in Q4 2025, and $99.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 439.40 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 52.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.70 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 39.74 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 335,572.77 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 218.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 82.05 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Upstream Bio | 387.23 Mn | 387.23 Mn | -3.29 Mn | 9.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 9.16 Mn |
| Jun 30, 2026 | 9.16 Mn |
| Mar 31, 2026 | 21.23 Mn |
| Mar 31, 2026 | 21.23 Mn |
| Dec 31, 2025 | 162.28 Mn |
| Dec 31, 2025 | 162.28 Mn |
| Sep 30, 2025 | 99.54 Mn |
| Sep 30, 2025 | 99.54 Mn |
| Jun 30, 2025 | 39.69 Mn |
| Jun 30, 2025 | 39.69 Mn |
| Mar 31, 2025 | 7.59 Mn |
| Mar 31, 2025 | 7.59 Mn |
| Dec 31, 2024 | 71.27 Mn |
| Dec 31, 2024 | 71.27 Mn |
| Sep 30, 2024 | 35.09 Mn |
| Sep 30, 2024 | 35.09 Mn |
| Dec 31, 2023 | 39.70 Mn |
| Dec 31, 2023 | 39.70 Mn |